



Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMTunmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial

2022**ASCO** Abstract #2050


Frank A. Giordano¹, Julian P. Layer^{1,2}, Sonia Leonardelli², Lea L. Friker³, Clemens Seidel⁴, Christina Schaub⁵, Roberta Turiello², Elena Sperk⁶, Franziska Grau⁷, Daniel Paech⁷, Barbara Link¹, Wolf Mueller⁸, Ghazaleh Tabatabai⁹, Katharina Sahm¹⁰, Sied Kebir¹¹, Torsten Pietsch³, Martin Glas¹¹, Sotirios Bisdas¹², Ulrich Herrlinger⁵, Michael Hölzel²


¹ Department of Radiation Oncology, University Hospital Bonn; ² Institute of Experimental Oncology, University Hospital Bonn; ³ Department of Neuropathology, University Hospital Bonn; ⁴ Department of Radiotherapy, University Hospital Leipzig; ⁵ Department of Neurology, University Hospital Bonn; ⁶ Department of Radiation Oncology, University Hospital Mannheim, University of Heidelberg; ⁷ Department of Neurology, University Hospital Bonn; ⁸ Institute of Neuropathology, University Hospital Leipzig; ⁹ Department of Neurology, University Hospital Tübingen; 10 Department of Neurology, University Hospital Mannheim, University of Heidelberg; 11 Department of Neurology, University Hospital Essen; 12 Department of Neurology, National Hospital for Neurology London





Exploratory Endpoint: Translational characterization of TME response by CODEX®





- Trial results were compared to a matched imaging reference cohort treated with standard of care (SOC)
- Of 10 patients, one had only target lesions (TLs) and another one had only non target lesions (NTLs)
- 9/10 patients showed response to NOX-A12 either in TL or NTL
- 8/9 patients with detectable TLs responded to NOX-A12, 4/9 reaching partial remission (PR; n = 2 at DL1 and n = 2 at DL3)
- 3/3 patients of DL1 and 4/4 of DL3 reached PR or CR of one or more NTLs • In 3/9 cases (n = 2 at DL1; n = 1 at DL3), at least one NTL completely disappeared


Radiotherapy + NOX-A12 in chemotherapy refractory GBM


CD8 T cells

Safe | No DLT | Promising clinical efficacy | T cell recruitment + clustering Expansion arms with Bevacizumab or Pembrolizumab initiated



C3-001





TUMOR MICROENVIRONMENT

Matched pre-/post-surgery CODEX® reveals recruitment and cluster formation of proliferating cytotoxic T cells (upper panel) Matched pre-/post-surgery CODEX® of non-responding patient show T-cell encapsulation by M2-like macrophages (lower panel)

REGISTRATION & CONTACT

Registered with clinicaltrials.gov, ID: NCT04121455

Frank.Giordano@ukbonn.de